title: Phase II study of amonafide in advanced pancreatic adenocarcinoma.
abstract: To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial. The starting dose was 400 mg/m2 administered daily over 1 hr for 5 consecutive days repeated every 3 weeks. Because of grade 4 myelosuppression observed in the initial 2 patients, the daily starting dose was decreased to 350 mg/m2. Of the 15 patients, 14 were evaluable. Amonafide failed to produce clinical responses in the doses and schedule employed. Grade 4 granulocytopenia was observed in 3 of 9 courses at 400 mg/m2, 3 of 12 courses at 350 mg/m2 and in 1 of 4 courses at 300 mg/m2. Grade 4 thrombocytopenia was observed in 3 courses at 400 mg/m2. Nonhematologic toxicities included mild nausea and vomiting and skin rashes.
authors.affiliation: Division of Medicine, University of Texas M.D. Anderson Cancer Center, Houston.
authors.forename: K
authors.initials: K
authors.lastname: Linke
authors.forename: R
authors.initials: R
authors.lastname: Pazdur
authors.forename: J L
authors.initials: JL
authors.lastname: Abbruzzese
authors.forename: J A
authors.initials: JA
authors.lastname: Ajani
authors.forename: R
authors.initials: R
authors.lastname: Winn
authors.forename: J E
authors.initials: JE
authors.lastname: Bradof
authors.forename: K
authors.initials: K
authors.lastname: Daugherty
authors.forename: B
authors.initials: B
authors.lastname: Levin
mesh_terms: D000225:Adenine; D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007094:Imides; D007546:Isoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D053644:Naphthalimides; D063065:Organophosphonates; D010190:Pancreatic Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D007094:Imides; D007546:Isoquinolines; D053644:Naphthalimides; D063065:Organophosphonates; C037020:amonafide; D000225:Adenine